" class="no-js "lang="en-US"> Collective Health Announces Appointment of Linda Grais to Board
Thursday, March 28, 2024

Collective Health Announces Appointment of Dr. Linda Grais to Board of Directors

Collective Health has announced the addition of Dr Linda Grais, a seasoned physician and biopharma entrepreneur and CEO, to its board of directors.

Informed by her breadth of healthcare experience as a physician, investor, founder, and leader, Dr. Grais’ deep passion for working at the intersection of medicine and technology has fueled her belief that technology-driven platforms and solutions, like Collective Health, are critical to changing outcomes in healthcare.

“Over the course of my career, I’ve come to understand the unique challenges facing our healthcare system and to recognize the power that technology can bring to build something better,” Dr. Grais said. “Collective Health has created a solution that is changing the way we approach the business of healthcare. By harnessing the latest advances in software technology, Collective Health is delivering exceptional member experience and is leveraging data and analytics to create a more transparent, understandable, and effective healthcare system. I am thrilled to support Collective Health’s goal of driving better health and financial outcomes for employers and their people.”

Previously, Dr. Grais served as President, Chief Executive Officer, and member of the Board of Directors of Ocera Therapeutics, a biopharmaceutical company developing novel treatments for gastrointestinal and liver diseases, from 2012 until it was acquired in 2017. Previously, she was a Partner at InterWest Partners, a venture capital firm investing in drug development and medical device companies. Dr. Grais was a founder and executive vice president of Structural GenomiX, which pioneered the use of genomics and proteomics to accelerate drug discovery, and which was acquired by Eli Lilly after going public. Dr. Grais trained in Internal and Critical Care Medicine at the University of California, San Francisco, where she was Assistant Clinical Professor. Dr. Grais is currently a Lecturer in Management at the Stanford Graduate School of Business

“Dr. Linda Grais is no stranger to the challenges that our healthcare system presents,” said Ali Diab, Founder and CEO of Collective Health. “As a multi-faceted healthcare business leader, investor, and clinical expert, Dr. Grais brings a truly unique and highly valuable perspective, with her experience touching nearly every aspect of our healthcare system. Her belief that technology can and should play a key role in enabling better health outcomes is strongly aligned with Collective Health’s mission to leverage data and technology and world-class user experience design to make our healthcare system work better for employers and their people. I am delighted to welcome Dr. Grais to our board, and look forward to leveraging her perspective and expertise as we continue to scale the company into the future.”

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more